Oculomotor and Spatial Cognition Deficits in Schizophrenia

Not Applicable

Terminated

• Conditions: Schizophrenia
• Interventions: Drug: Antipsychotic

• Registration Number: NCT00931996
• Lead Sponsor: University of Illinois at Chicago

Brief Summary

DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia. However, the regional disturbances in brain function causing these deficits are not yet known. This application proposes a series of integrated behavioral studies designed to identify causes of deficits in schizophrenia.

Detailed Description

We will be assessing clinical symptoms and cognition before and after treatment.

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2009-06-25
• Study First Submitted QC: 2009-07-01
• Study First Posted: 2009-07-02
• Primary Completion: 2011-11
• Study Completion: 2011-11
• Results First Submitted: 2011-11-08
• Status Verified: 2013-01
• Results First Submitted QC: 2013-01-23
• Last Update Submitted: 2013-01-23
• Results First Posted: 2013-01-24
• Last Update Posted: 2013-01-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Inclusion Criteria: Inclusion criteria for this study are (1) able and willing to give written informed consent; (2) no contraindications to MRI (cardiac pacemaker, aneurysm clip, cochlear implants, IUD, shrapnel, history of metal fragments in eyes, neurostimulators or other metal devices, weight of 250lbs or more, claustrophobia) and (3) medically stable. Sedation will not be used for MRI studies because cooperation is essential.

Exclusion Criteria

• Any subject is excluded from the imaging studies if they have any contraindications to MRI such as cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy in the later stages (because of body size and limited comfort for MRI studies), IUD, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia. Individuals with mental retardation, neurologic disease or significant medical illness that might effect neuronal or vascular physiology will not be recruited.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Antipsychotic	Antipsychotic	Antipsychotic

Primary Outcome Measures

Name	Time	Method
Positive and Negative Syndrome Scale (PANSS) Score Change From Baseline.	Baseline and 6 weeks	Positive and Negative Syndrome Scale (PANSS) Total Score. 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. PANSS Total score minimum = 30, maximum = 210 Higher scores represent more severe symptoms. A positive change score (baseline-6 weeks) indicates an improvement in symptoms.

Trial Locations

Locations (1)

UIC Center for Cognitive Medicine; 🇺🇸 Chicago, Illinois, United States